|
Overview

  • Anticoagulants decrease the formation of fibrin clots
    • heparin
    • warfarin (coumadin)
    • bivalirudin
Heparin
  • Mechanism
    • catalyzes the binding of antithrombin III to multiple clotting factors  
    • inactivates several factor
      • IIa (thrombin)
      • Xa
      • IXa
      • XIa
      • XIIa
  • Clinical use
    • immediate anticoagulation
      • pulmonary embolism
      • acute coronary syndrome
      • stroke
      • MI
      • DVT
      • DIC
    • during pregnancy
      • does not cross placenta
  • Toxicity
    • bleeding
    • osteoporosis
    • heparin-induced thrombocytopenia (HIT)
      • heparin binds to platelet factor IV
      • antibodies bind to and activate platelets
      • leads to hypercoagulable state and thrombocytopenia
    • hypersensitivity
  • Pharmacology
    • IV delivery only for theurapeutic anticoagulation
    • short half-life (2h)
    • large, water-soluble polysaccharide
    • low-molecular-weight heparins (e.g. enoxaparin) have advantages of
      • longer half-lives (2-4x)
      • less thrombocytopenia
      • enhanced activity against factor Xa
      • administered subcutaneously without laboratory (PTT) monitoring
      • not easily reversible
  • Monitoring
    • partial thromboplastin time (PTT
  • Antagonist
    • protamine sulfate 
      • positively charged to bind negatively charged heparin
Warfarin (coumadin)
  • Mechanism
    • ↓ hepatic synthesis of vitamin K-dependent clotting factors
      • prevents the reduction of vitamin K, a necessary step in the synthesis of clotting factors
        • vitamin K epoxide reductase is inhibited
        • γ-carboxylation of clotting factors cannot occur 
      • affected clotting factors include
        • II
        • VII
        • IX
        • X
        • protein C
        • protein S
    • no effect on clotting factors already present
    • affects the extrinsic pathway
  • Clinical use
    • chronic anticoagulation
      • DVT prophylaxis
      • post-STEMI
      • heart valve damage
      • atrial arrhythmias
  • Toxicity
    • transient hypercoagulability
      • transient protein C deficiency when beginning warfarin treatment
        • due to short half life of protein C
      • can lead to skin necrosis and dermal vascular thrombosis
        • pain, bullae formation, and skin necrosis following initiation of warfarin likely has warfarin-induced skin necrosis
        • often occurs in women who have protein C deficiency
        • treatment includes administration of vitamin K and discontinuation of warfarin 
      • give heparin as you begin warfarin treatment
    • bleeding
      •  retroperitoneal hematoma - back/abdominal pain and hemodynamic compromise 
        • CT scan to identify and guide treatment
    • teratogenic
      • bone dysmorphogenesis
      • not used in pregnancy
    • drug interactions
      • P450 metabolism 
        • inducers → ↓ PT
          • increase in P450 degrades more warfarin and levels fall
          • carbamazepine, barbiturates, rifampin
        • inhibitors → ↑ PT
          • decrease in P450 degrades less warfarin and levels rise
          • macrolides, cimetidine, imidazoles
      • ASA, sulfonamides, phenytoin
        • displace warfarin from plasma proteins, leading to increased free fraction → ↑ PT
      • cholestyramine
        • ↓ oral absorption
          • due to low pKa
  • Pharmacology
    • oral
    • long half life (>30 hr)
    • small, lipid-soluble
  • Monitoring
    • prothrombin time (PT)
    • INR
      • (tested PT / reference PT)^(calibration value)
  • Antagonist
    • vitamin K (slow onset)
    • fresh frozen plasma (fast onset)  
Lepirudin, bivalirudin
  • Mechanism
    • direct inihibtors of thrombin (IIa)
  • Clinical use
    • alternative to heparin
      • e.g. during HIT
    • unstable angina during percutaneous transluminal coronary angioplasty
 

Please rate topic.

Average 4.0 of 3 Ratings

Questions (4)
EVIDENCE & REFERENCES (7)
POSTS (1)
Topic COMMENTS (8)
Private Note